Clinical Science
Metabolic dysfunction-associated steatohepatitis (MASH) has historically lacked effective pharmacological treatments. New clinical data shows GLP-1 therapies are fundamentally changing this trajectory.
As dual agonists like tirzepatide reshape obesity treatment, the next frontier—triple agonists targeting GLP-1, GIP, and glucagon receptors—is showing unprecedented efficacy in early clinical trials.
Discover the profound cardiovascular and metabolic benefits of GLP-1 therapies beyond weight loss, from heart health to neuroprotection.
An in-depth look at the manufacturing bottlenecks causing ongoing shortages of GLP-1 therapies and what it means for patient access in 2026.
Recent clinical data highlights the potential of GLP-1 medications to significantly improve Obstructive Sleep Apnea (OSA) severity, expanding their role in comprehensive metabolic care.
Exploring the profound cardiovascular and metabolic benefits of GLP-1 receptor agonists beyond weight loss.
A comprehensive guide to managing the common gastrointestinal side effects of GLP-1 medications and strategies to preserve lean muscle mass during treatment.
Board-certified physicians, quarterly labs, muscle-preserving protocols, supplement Rx, and resistance training guidance — all included.
See the Program →